NASDAQ · Drug Manufacturers - General · USD

MIRA Pharmaceuticals, Inc. (MIRA) Stock Analysis

MIRA Pharmaceuticals, Inc. (MIRA) is a Drug Manufacturers - General stock listed on NASDAQ and quoted in US Dollar.

MIRA

$0.76

+$0.02 (+3.24%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare MIRA with… →

MIRA Key Statistics

As of Sep 4, 2026

Trading

Open: $0.74
Previous Close: $0.74
Day's Range: 0.74–0.85
52-Week Range: 0.60–2.45
Volume: 338.50K
Beta: 1.53

Valuation

Market Cap: $32.10M
P/E Ratio: unprofitable
EPS (ttm): −1.22

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$10.44M
Profit margin: 0.00%
Shares Outstanding: 42.02M
1-Year Return: −44.64%

Dividend and dates

Avg Volume: 564.76K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

MIRA Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

−85.85%+8.57%+32.46%−49.40%

2023*202420252026*

Year	Return
2026 (partial year)	−49.40%
2025	+32.46%
2024	+8.57%
2023 (partial year)	−85.85%

As of September 4, 2026.

MIRA Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$10.44M	—
2024	$0.00	−$7.85M	—
2023	$0.00	−$11.98M	—
2022	$0.00	−$7.06M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$10.49M	−$10.44M	—
2024	$0.00	—	−$8.02M	−$7.85M	—
2023	$0.00	—	−$8.53M	−$11.98M	—
2022	$0.00	—	−$7.05M	−$7.06M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

MIRA Valuation vs Drug Manufacturers - General Median

Median of 21 stocks

Metric	MIRA	Drug Manufacturers - General median	vs median
Profit margin	0.00%	8.09%	8.1 pts below

Medians across 21 Drug Manufacturers - General stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Analysis

Data-derived

Company Overview

The market values MIRA Pharmaceuticals, Inc. (MIRA) at $32.10M. The company sits in the Healthcare sector, in the Drug Manufacturers - General industry.

The 52-week range on file runs from $0.60 to $2.45. The most recent close on file for MIRA is $0.76, dated September 4, 2026. That is +$0.02 (+3.24%) against the previous close. The latest close sits 27.33% above that 52-week low.

Financial Health

In fiscal 2025, MIRA Pharmaceuticals, Inc. reported revenue of $0.00. The same year closed with a net loss of $10.44M. The reported profit margin is 0%. That is 8.1 percentage points below the Drug Manufacturers - General median of 8.09%. Earnings per share on a trailing basis come to −1.22.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative.

Over the trailing twelve months the price has returned −44.64%. Measured over 3 years, that is −50.18% a year compounded. The reported beta is 1.54. Daily returns over the trailing 3 years annualize to a volatility of 384.79%.

Growth & Income

The record shows no dividend for MIRA.

Across the complete calendar years on file, 2025 returned +32.46% and 2024 returned +8.57%. So far in 2026 the price is −49.40%.

Peer Comparison

MIRA Pharmaceuticals, Inc. (MIRA) operates in the Drug Manufacturers - General industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
MIRA Pharmaceuticals, Inc.	MIRA	$32.10M	—
Eli Lilly and Company	LLY	$1.02T	38.6
Johnson & Johnson	JNJ	$663.28B	32.0
AbbVie Inc.	ABBV	$453.19B	73.5

The Drug Manufacturers - General industry average P/E ratio is 24.7x. MIRA Pharmaceuticals, Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Drug Manufacturers - General Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

NVS

Novartis AG

$304.10B

AZN

AstraZeneca PLC

$252.33B

View all Drug Manufacturers - General stocks →

Popular Healthcare Stocks

UNH

UnitedHealth Group Incorporated

$356.47B

AMGN

Amgen Inc.

$236.38B

TMO

Thermo Fisher Scientific Inc.

$226.94B

NVO

Novo Nordisk A/S

$206.02B

ABT

Abbott Laboratories

$187.45B

View all Healthcare stocks →

About MIRA Pharmaceuticals, Inc.

MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.

Visit website →